John O. Miners - Publications, H-index & Citations

John O. Miners

flinders university

80H指数

359论文数

2.1W被引数

收录论文 95

发表时间

Reply to Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-12-01

PREAI

Miners, John O.; Polasek, Thomas M.

Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.基于体外动力学数据的胆红素肝摄取和葡糖醛酸化PBPK建模需谨慎：对Dong等人文章的评论

Clinical Pharmacology & Therapeutics

IF5.5

2025-05-26

OAAI

John O. Miners; Thomas M. Polasek

The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2023-12-01

OAAI

Nair, Pramod C.; Burns, Kushari; Chau, Nuy; Mckinnon, Ross A.; Miners, John O.

Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance 改变葡萄糖醛酸化药物暴露的药物-药物相互作用: 范围，UDP-葡萄糖醛酸基转移酶 (UGT) 酶选择性，机制 (抑制和诱导) 和临床意义

PHARMACOLOGY & THERAPEUTICS

IF12.5

2023-08-01

PREAI

Miners, John O.; Polasek, Thomas M.; Hulin, Julie-Ann; Rowland, Andrew; Meech, Robyn

Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2021-09-01

PREAI

Kichenadasse, Ganessan; Miners, John O.; Mangoni, Arduino A.; Karapetis, Christos S.; Hopkins, Ashley M.; Sorich, Michael J.

Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs

MOLECULAR PSYCHIATRY

IF10.1

2021-08-10

PREAI

Nair, Pramod C.; Miners, John O.; McKinnon, Ross A.; Langmead, Christopher J.; Gregory, Karen J.; Copolov, David; Chan, Sherry Kit Wa; Bastiampillai, Tarun

Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping

PHARMACOLOGY & THERAPEUTICS

IF12.5

2021-02-01

PREAI

Miners, John O.; Rowland, Andrew; Novak, Jonathan J.; Lapham, Kimberly; Goosen, Theunis C.

Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes

JOURNAL OF HYPERTENSION

IF4.1

2021-01-18

PREAI

Kichenadasse, Ganessan; Miners, John O.; Mangoni, Arduino A.; Rowland, Andrew; Sorich, Michael J.; Hopkins, Ashley M.

Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure

AAPS JOURNAL

IF3.7

2021-01-06

PREAI

Badaoui, Sarah; Hopkins, Ashley M.; Rodrigues, A. David; Miners, John O.; Sorich, Michael J.; Rowland, Andrew

Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity

MOLECULAR PHARMACOLOGY

IF3

2020-12-01

OAAI

Nair, Pramod C.; Chau, Nuy; McKinnon, Ross A.; Miners, John O.

Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2020-09-01

OAAI

Cheong, Eleanor Jing Yi; Nair, Pramod C.; Neo, Rebecca Wan Yi; Ho Thanh Tu; Lin, Fu; Chiong, Edmund; Esuvaranathan, Kesavan; Fan, Hao; Szmulewitz, Russell Z.; Peer, Cody J.; Figg, William D.; Chai, Christina Li Lin; Miners, John O.; Chan, Eric Chun Yong

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2020-09-01

OAAI

Kichenadasse, Ganessan; Miners, John O.; Mangoni, Arduino A.; Rowland, Andrew; Hopkins, Ashley M.; Sorich, Michael J.

Binding of clozapine to the GABAB receptor: clinical and structural insights

MOLECULAR PSYCHIATRY

IF10.1

2020-03-13

PREAI

Nair, Pramod C.; McKinnon, Ross A.; Miners, John O.; Bastiampillai, Tarun

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202

BIOCHEMICAL PHARMACOLOGY

IF5.6

2019-11-01

PREAI

Korprasertthaworn, Porntipa; Chau, Nuy; Nair, Pramod C.; Rowland, Andrew; Miners, John O.

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations CYP2C9的药物基因组学: 功能和临床考虑

JOURNAL OF PERSONALIZED MEDICINE

IF3

2017-12-28

143

OAAI

Daly, Ann K.; Rettie, Allan E.; Fowler, Douglas M.; Miners, John O.

Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2017-11-03

OAAI

Miners, John O.; Pattanawongsa, Attarat; Rowland, Andrew

The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance 肾脏在药物清除中的作用: 转运，代谢和肾脏疾病对药物清除的影响

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2017-07-26

PREAI

Miners, J. O.; Yang, X.; Knights, K. M.; Zhang, L.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia

BIOCHEMICAL PHARMACOLOGY

IF5.6

2017-04-01

PREAI

Miners, John O.; Chau, Nuy; Rowland, Andrew; Burns, Kushari; McKinnon, Ross A.; Mackenzie, Peter I.; Tucker, Geoffrey T.; Knights, Kathleen M.; Kichenadasse, Ganessan

Advances in drug metabolism and pharmacogenetics research in Australia

PHARMACOLOGICAL RESEARCH

IF10.5

2017-02-01

PREAI

Mackenzie, Peter I.; Somogyi, Andrew A.; Miners, John O.

Haemodynamic effects of parenteral vs. enteral paracetamol in critically ill patients: a randomised controlled trial

ANAESTHESIA

IF6.9

2016-09-09

OAAI

Kelly, S. J.; Moran, J. L.; Williams, P. J.; Burns, K.; Rowland, A.; Miners, J. O.; Peake, S. L.

研究方向